SCYNEXIS, Inc. announced the retirement of Chief Financial Officer Ivor Macleod and the appointment of Sanjay Subramanian as his successor, effective September 9, 2026. Mr. Macleod will remain with the company through October 9, 2026 to facilitate a transition. Mr. Subramanian’s employment agreement includes an annual base salary of $500,000, a one-time sign-on bonus of $20,000, and a discretionary performance bonus of up to 40% of his base salary. He received a stock option to purchase 100,000 shares at an exercise price of $4.91 per share, vesting over four years. The agreement also outlines severance provisions, including nine months of base salary and accelerated equity vesting upon termination without cause or for good reason, increasing to eighteen months following a change of control. SCYNEXIS operates in the biotechnology industry, developing innovative therapies for severe rare diseases.

SCYNEXIS, Inc. stockholders at the June 25, 2026 Annual Meeting approved an amendment to its Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 60,000,000 shares (pre-reverse stock split). The company also filed a Registration Statement on Form S-3 to register the resale of up to 87,000,000 shares of Common Stock, including shares held by selling stockholders and shares issuable upon the exercise of pre-funded and common warrants. SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing specialty antibiotic treatments.